Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - sodium alginate; sodium bicarbonate; calcium carbonate - oral suspension - 500mg+267mg+160 milligram/ 10 millilitre - salt solutions; sodium bicarbonate

Israel - English - Ministry of Health

lapidot medical import and marketing ltd - sodium bicarbonate - solution for infusion - sodium bicarbonate 8.4 %w/v - salt solutions - metabolic acidosis, urine alkalization.

United States - English - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium gluconate (unii: r6q3791s76) (sodium cation - unii:lyr4m0nh37, gluconic acid - unii:r4r8j0q44b), sodium acetate (unii: 4550k0sc9b) (sodium cation - unii:lyr4m0nh37, acetate ion - unii:569dqm74sc), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - uni - sodium chloride 0.53 g in 100 ml - this solution is indicated for use in adults as a source of electrolytes and water for hydration, and as an alkalinizing agent. contraindications: none known. accurate clinical and laboratory estimation of fluid and electrolyte balance in order to access benefit/risk ratio are essential prior to administration of this solution (see warnings and precautions ).

United States - English - NLM (National Library of Medicine)

general injectables and vaccines, inc - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 0.2 g in 5 ml - neut (4% sodium bicarbonate additive solution) is indicated for use asa an additive to raise the ph of acid solutions administered intravenously to reduce the incidence of chemical phlebitis and patient discomfort due to vein irritation at or near the site of infusion. not for use as a systemic alkalizer. none known.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 650 mg

United States - English - NLM (National Library of Medicine)

hospira, inc. - sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 0.2 g in 5 ml - neut (4% sodium bicarbonate additive solution) is indicated for use as an additive to raise the ph of acid solutions administered intravenously to reduce the incidence of chemical phlebitis and patient discomfort due to vein irritation at or near the site of infusion. not for use as a systemic alkalizer. none known.

United States - English - NLM (National Library of Medicine)

app pharmaceuticals, llc - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 42 mg in 1 ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alturix ltd - sodium dihydrogen phosphate anhydrous - effervescent tablet - 1.936gram

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 100 mg/ml; disodium edetate, quantity: 60 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, constipation, headache, leg cramps, black stools, oliguria, stupor, convulsions, palsies and coma. chronic lead poisoning causes variable involvement of the central n

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see warnings and precautions (5) ]. none. risk summary available data with sodium phenylacetate and sodium benzoate injection use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with sodium phenylacetate and sodium benzoate injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.